Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 8/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538326 | 0.83 | MDM2 (0.40) | MDM2TP53FNTAFNTBHTT | |
| SCHEMBL6510724 | 0.80 | OPRK1 (0.46) | MEN1KMT2ATRPM4TRPM5 | |
| SCHEMBL18319671 | 0.79 | LMNA (0.41) | MDM2FNTAFNTB | |
| SCHEMBL5557771 | 0.78 | MDM2 (0.38) | MDM2TP53FNTAFNTBMEN1 | |
| SCHEMBL4373317 | 0.74 | FNTA (0.59) | FNTAFNTB | |
| SCHEMBL10415997 | 0.74 | GABRP (0.43) | HTTMEN1KMT2A | |
| SCHEMBL5555500 | 0.71 | MEN1 (0.47) | MDM2TP53HTTMEN1KMT2A | |
| SCHEMBL13501490 | 0.71 | ALDH1A1 (0.35) | FNTAFNTBMEN1KMT2AHDAC1 | |
| SCHEMBL6585222 | 0.69 | CYP1A2 (0.42) | MEN1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL5556337 | 0.68 | PDE4A (0.41) | MDM2TP53FNTAFNTBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339709-B1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | disclosed |
| US-7153958-B2 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-26 | — | — | US | disclosed |
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1339709-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042296-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | FNTA, FNTB, RCE1 | MDM2 2820/4885TP53 2218/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.